ZURICH, June 29: Swiss drugmaker Roche said yesterday that European regulators had given a green light to a new formulation of its breast cancer drug Herceptin, which it hopes will help extend the medicine’s shelf life. The European Medicines Agency (EMA) said that its experts had recommended approval of a new injectable version of Herceptin, which cuts down treatment time to just two to five minutes. It currently takes between 30 to 90 minutes to administer the drug intravenously. (agencies)
Follow our WhatsApp channel